Flare, Xaman Roll Out One-Click DeFi Vault for XRP Yield via XRPL Wallets 
Meta Signs Multi-Billion Dollar AI Chip Deal With Google to Power Next-Gen AI Models 
China’s New Home Prices Post Sharpest Drop Since 2022 Amid Ongoing Property Slump 
Samsung and SK Hynix Shares Hit Record Highs as Nvidia Earnings Boost AI Chip Demand 
Malta will gain from smart heritage 
APEX Tech Acquisition Inc. Raises $111.97 Million in NYSE IPO Under Ticker TRADU 
ASX CEO Exit Signals Turbulent Transition Amid Lawsuit and Regulatory Scrutiny 
FAA Plans Flight Reductions at Chicago O’Hare as Airlines Ramp Up Summer Schedules 
Gold Prices Rally in February as Geopolitical Risks and Economic Uncertainty Boost Safe-Haven Demand 
Japan Manufacturing PMI Jumps to Four-Year High as Global Demand Strengthens 
Australia Targets AI Platforms With Strict Age Verification Rules 
Wall Street Futures Tumble as U.S.-Iran Conflict Escalates and Oil Prices Surge 
Netflix Stock Jumps 14% After Exiting Warner Bros Deal as Paramount Seals $110 Billion Acquisition 
PBOC Scraps Forex Risk Reserve as Yuan Rally Pressures Chinese Exporters 
Oil Prices Surge 13% as U.S.-Israel Strikes on Iran Spark Supply Fears 
Australian Job Advertisements Hit 16-Month High as Labour Market Stays Resilient 
Celltrion revealed the results of its phase 3 clinical trial for its COVID-19 treatment drug called Regkirona. The final testing was said to have yielded good results, and the biopharmaceutical company headquartered in Incheon, South Korea, presented it at a conference in Europe.
The effectiveness of Celltrion’s Regkirona
As per The Korea Herald, Celltrion said on Tuesday, July 13, that its anti-body COVID-19 treatment can reduce the risk of the infection from becoming a severe case by 70%. Based on the final round of tests, the high-risk groups showed a reduced progression rate to severe infection by 72%.
The patients who were administered the Regkirona treatment were able to recover from COVID-19 in just 8.4 days. This was said to be 4.9 days faster compared to patients who used placebo treatment and recovered for 13.3 days.
For high-risk groups, Celltrion’s anti-body treatment helped patients recover for 9.3 days which is likewise faster by 4.7 days compared to the placebo group who recovered in 14 days. Moreover, the Korean biopharmaceutical company further discovered that its treatment significantly reduced viral titers in patients after they were given Regkirona.
Most importantly, there were no severe adverse effects or allergic reactions detected. Besides the mild and temporary reactions from patients, there have been no reports of severe responses to the drug. While the results of the trial were good, Celltrion is still testing if the treatment is also effective against other variants of COVID-19, such as the delta.
The presentation in Europe
The results of Celltrion’s antibody COVID-19 treatment were presented in Europe by Oana Sandulescu, who is an associate professor at Carol Davila University of Medicine and Pharmacy. She shared the results during the 31st European Congress of Clinical Microbiology and Infectious Diseases that was held online from July 9 to 12, according to The Korea Economic Daily.
Sandulescu attested that Regkirona significantly lowered the rate of progression for severe coronavirus infection symptoms and hastened the recovery time too. In any case, the associate professor took part in the clinical trial of Regkirona that was conducted from January to April with 1,315 participants from 13 countries.
